More Industry News

  • GSK is evaluating acquisitions in India, CEO says

    GlaxoSmithKline is considering deals to buy or work with Indian drugmakers, according to this article. In a Q-and-A, CEO Andrew Witty said the company will reduce the price of its drugs in India to extend its reach with low-income consumers. The drugmaker will also collaborate with local companies to cut production costs, Witty said. GSK is interested in acquisitions to increase its business in India, but only at the right price, he said.

    Read more

  • Abbott will acquire Facet Biotech for about $450 million

    Abbott Laboratories will pay about $450 million to acquire Facet Biotech, a deal that is expected to conclude during the second quarter. The transaction, which was approved by both firms' boards of directors, will give Abbott access to Facet's daclizumab, a multiple sclerosis drug candidate, and other biotech drugs.

    Read more

  • D-Pharm chief has high hopes for stroke treatment candidate

    The FDA might allow D-Pharm to skip another Phase III trial of stroke drug DP-b99 if the first one agrees with positive results from a midstage study, CEO Alex Kozak said. The compound might be launched by the end of 2013 if study goals are met, Kozak said.

    Read more

  • GSK, Cellzome form new partnership for inflammatory disease drugs

    GlaxoSmithKline reached an agreement with Cellzome to develop tablet medicines for inflammatory diseases, including rheumatoid arthritis and lupus. The deal, worth as much as $690 million, builds on a 2008 collaboration that also involved Cellzome's epigenetics technology.

    Read more

  • Teva names Frost as chairman and Many as vice chairman

    Teva Pharmaceutical Industries Vice Chairman Phillip Frost and Interim Chairman Moshe Many will switch responsibilities permanently. Frost is also the chairman of Prolor Biotech and the chairman and CEO of specialty drugmaker Opko Health.

    Read more

  • Auxilium launches Dupuytren's contracture drug Xiaflex

    Auxilium Pharmaceuticals rolled out Xiaflex, a drug for hand disease Dupuytren's contracture, through a distribution network of health care providers, pharmacies and wholesalers. The treatment received FDA approval as a prescription medication Feb. 3.

    Read more

Powered by SmartBrief